Getting high level care to low and middle income countries
Getting high level care to low and middle income countries
Tackling the increase in cancer cases worldwide
How will ASCO combat cancer disparities?
Chemotherapy-free strategies in treating leukaemia
Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients
Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL
CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy
ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients with FLT3-mutated relapsed/refractory AML
Multiple myeloma science from EHA 2019
CAR T-cell therapy for treating acute leukaemia
Selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia
ECHELON-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma